|
English
|
正體中文
|
简体中文
|
總筆數 :0
|
|
造訪人次 :
50695675
線上人數 :
202
教育部委託研究計畫 計畫執行:國立臺灣大學圖書館
|
|
|
"kwak e l"的相關文件
顯示項目 1-7 / 7 (共1頁)
1
每頁顯示[10|25|50]項目
| 臺大學術典藏 |
2021-08-31T06:42:27Z |
A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and pharmacokinetics of intravenous TLC388 administered to patients with advanced solid tumors
|
Ghamande S.; Lin C.-C.; Cho D.C.; Shapiro G.I.; Kwak E.L.; Silverman M.H.; Tseng Y.; Kuo M.-W.; Mach W.B.; Hsu S.-C.; Coleman T.; Yang J.C.-H.; ANN-LII CHENG; Ghalib M.H.; Chuadhary I.; Goel S. |
| 臺大學術典藏 |
2020-05-26T09:27:00Z |
A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and pharmacokinetics of intravenous TLC388 administered to patients with advanced solid tumors
|
Ghamande S; Lin C.-C; Cho D.C; Shapiro G.I; Kwak E.L; Goel S.; Chuadhary I; Ghalib M.H; Cheng A.-L; CHIH-HSIN YANG; Coleman T; Silverman M.H; Tseng Y; Kuo M.-W; Mach W.B; Hsu S.-C |
| 臺大學術典藏 |
2020-05-25T07:35:23Z |
A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and pharmacokinetics of intravenous TLC388 administered to patients with advanced solid tumors
|
Ghamande S; Chia-Chi Lin; Cho D.C; Shapiro G.I; Kwak E.L; Silverman M.H; Tseng Y; Kuo M.-W; Mach W.B; Hsu S.-C; Coleman T; Yang J.C.-H; Cheng A.-L; Ghalib M.H; Chuadhary I; Goel S. |
| 臺大學術典藏 |
2020-02-14T02:49:50Z |
Phase 2 trial of afatinib, an ErbB family blocker, in solid tumors genetically screened for target activation
|
Kwak E.L.; Shapiro G.I.; Cohen S.M.; Becerra C.R.; Lenz H.-J.; WEN-FANG CHENG; Su W.-C.; Robohn M.; Le Maulf F.; Lobmeyer M.T.; Chand V.K.; Iafrate A.J. |
| 臺大學術典藏 |
2020-02-06T05:22:03Z |
Phase 2 trial of afatinib, an ErbB family blocker, in solid tumors genetically screened for target activation
|
Iafrate A.J.;Chand V.K.;Lobmeyer M.T.;Le Maulf F.;Robohn M.;Su W.-C.;WEN-FANG CHENG;Lenz H.-J.;Becerra C.R.;Cohen S.M.;Shapiro G.I.;Kwak E.L.; Kwak E.L.; Shapiro G.I.; Cohen S.M.; Becerra C.R.; Lenz H.-J.; WEN-FANG CHENG; Su W.-C.; Robohn M.; Le Maulf F.; Lobmeyer M.T.; Chand V.K.; Iafrate A.J.; Kwak E.L.; Shapiro G.I.; Cohen S.M.; Becerra C.R.; Lenz H.-J.; WEN-FANG CHENG; Su W.-C.; Robohn M.; Le Maulf F.; Lobmeyer M.T.; Chand V.K.; Iafrate A.J. |
| 臺大學術典藏 |
2020-02-06T05:22:03Z |
Phase 2 trial of afatinib, an ErbB family blocker, in solid tumors genetically screened for target activation
|
Iafrate A.J.;Chand V.K.;Lobmeyer M.T.;Le Maulf F.;Robohn M.;Su W.-C.;WEN-FANG CHENG;Lenz H.-J.;Becerra C.R.;Cohen S.M.;Shapiro G.I.;Kwak E.L.; Kwak E.L.; Shapiro G.I.; Cohen S.M.; Becerra C.R.; Lenz H.-J.; WEN-FANG CHENG; Su W.-C.; Robohn M.; Le Maulf F.; Lobmeyer M.T.; Chand V.K.; Iafrate A.J.; Kwak E.L.; Shapiro G.I.; Cohen S.M.; Becerra C.R.; Lenz H.-J.; WEN-FANG CHENG; Su W.-C.; Robohn M.; Le Maulf F.; Lobmeyer M.T.; Chand V.K.; Iafrate A.J. |
| 臺大學術典藏 |
2020-02-06T05:22:03Z |
Phase 2 trial of afatinib, an ErbB family blocker, in solid tumors genetically screened for target activation
|
Iafrate A.J.;Chand V.K.;Lobmeyer M.T.;Le Maulf F.;Robohn M.;Su W.-C.;WEN-FANG CHENG;Lenz H.-J.;Becerra C.R.;Cohen S.M.;Shapiro G.I.;Kwak E.L.; Kwak E.L.; Shapiro G.I.; Cohen S.M.; Becerra C.R.; Lenz H.-J.; WEN-FANG CHENG; Su W.-C.; Robohn M.; Le Maulf F.; Lobmeyer M.T.; Chand V.K.; Iafrate A.J.; Kwak E.L.; Shapiro G.I.; Cohen S.M.; Becerra C.R.; Lenz H.-J.; WEN-FANG CHENG; Su W.-C.; Robohn M.; Le Maulf F.; Lobmeyer M.T.; Chand V.K.; Iafrate A.J. |
顯示項目 1-7 / 7 (共1頁)
1
每頁顯示[10|25|50]項目
|
